Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Research analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for Structure Therapeutics in a ...

Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative ...

Physicians need to meet patients ‘where they are’ to develop a comprehensive plan to keep weight off and live a healthy ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Glucagon-like peptide-1 receptor agonists (GLP-1) drugs are a class of medications used to manage type 2 diabetes and treat ...

Many peptide medications like glucagon-like peptide-1 (GLP-1) receptor agonists were initially developed to treat type 2 diabetes. One unexpected side effect of these drugs is weight loss.

KOLs have questioned the safety profile of methadone, the current SOC. Credit: Stasonych via Shutterstock. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating ...